CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous Leukemia: A modified combination chemotherapeutic combination

摘要

With the emergence of novel drugs, ameliorated chemotherapy, molecular targeted therapy and hematopoietic stem cell transplant, complete remission (CR) rates for acute myelog-enous leukemia (AML) have markedly improved recently. In 1986, Griffin and Lowenberg reported that granulocyte colony-stimulating factor (G-CSF) played a role in the proliferation of leukemic progenitors in AML [1]. The application of G-CSF in AML treatment thus became a core concern. Yamada et al. [2] first applied a CAG regimen (cytarabine, aclacinomycin and G-CSF) to treat patients with AML in 1995, and they obtained dramatic results. Since then, priming regimens (including CAG, CHG [3] and HAG [4]; see Appendix for definitions) have been widely employed in AML and similar outcomes have been reported. However, their curative effects in refractory and relapsed AML (RR-AML) are still unsatisfactory.